Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Timothy Plan launches three new ETFs focusing on free cash flow and fixed income investing.

Others
05 May 2026
Timothy Partners, Ltd.
View Source
Bullish
pluang ai news

Timothy Plan has introduced three new ETFs: Free Cash Flow ETF (TPFC), Free Cash Flow Growth ETF (TPFG), and Fixed Income ETF (TPFI), all listed on the NYSE. The equity ETFs select companies based on strong free cash flow, a key measure of financial health, while the fixed income ETF invests in U.S. investment-grade bonds with active risk management. These ETFs expand Timothy Plan's Christian values-based investment options, appealing to investors seeking financial strength and income aligned with their beliefs. Victory Capital Management continues as sub-advisor, supporting the ETFs' strategies and growth potential.

More News

Nuvei to acquire Payoneer for $2.75B, boosting global payment platform capabilities.

Nuvei to acquire Payoneer for $2.75B, boosting global payment platform capabilities.

Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...

Company Fundamentals
Bullish
27 minutes ago
Eli Lilly's leukemia drug combo cuts disease progression risk by 45% in Phase 3 trial

Eli Lilly's leukemia drug combo cuts disease progression risk by 45% in Phase 3 trial

Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...

Market News
Bullish
32 minutes ago
Osteoarthritis market to grow 3% CAGR through 2036, fueled by new therapies and rising disease cases

Osteoarthritis market to grow 3% CAGR through 2036, fueled by new therapies and rising disease cases

The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...

Market News
Bullish
1 hour ago
Class action filed against Nano-X for alleged securities fraud, investors urged to join by Aug 11, 2026.

Class action filed against Nano-X for alleged securities fraud, investors urged to join by Aug 11, 2026.

A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...

Market News
Bearish
1 hour ago
Rhythm Pharma shares rise after positive 6-month data on obesity drug setmelanotide in Prader-Willi syndrome patients.

Rhythm Pharma shares rise after positive 6-month data on obesity drug setmelanotide in Prader-Willi syndrome patients.

Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App